Premenstrual Dysphoric Disorder Research
(Also Known As: Pmdd Research, PMS Research, Premenstrual Syndrome Research, Dysphoria Research, Mood Disorder Research)
(Reviewed by: Paul Peterson, Licensed Therapist)
Current Research on Premenstrual Dysphoric Disorder
Likewise, meta-analysis of fifteen randomized, placebo controlled studies revealed that using SSRIs in the treatment of premenstrual dysphoric disorder can be an effective and safe method of treating PMDD. Since SSRIs such as fluoxetine, citalopram, and clomipramine showed their effectiveness when used during the luteal phase, they are the only drugs that can be used as first-line therapy during the luteal phase. These drugs can lower the possibility of long term complications such as weight gain.
On October 2, 2007, a study entitled “Risk for Premenstrual Dysphoric Disorder Is Associated with Genetic Variation in ESR1, the Estrogen Receptor Alpha Gene" conducted by Liang Huo and his colleagues, discovered the first genetic link to premenstrual dysphoric disorder. The results of their study, which was published in the October 15th issue of the Biological Psychiatry revealed that women who have the gene estrogen receptor alpha is more likely to have premenstrual dysphoric disorder. 8
While the finding is just part of an initial report and requires further research, it represented a major step in establishing a genetic link to premenstrual dysphoric disorder. For Dr. David Rubinow, this is one way wherein there will be better understanding of the condition as well as of non-hormone associated depression.
In addition, studies concerning the efficacy of progesterone in the treatment of premenstrual dysphoric disorder have yielded limited advantages. In one study, it was found that progesterone is more powerful in treatment compared to placebo. However, other studies contradict these findings and reported that progesterone is less efficient and inferior to placebo.
Could You Have Premenstrual Dysphoric Disorder?
Premenstrual Dysphoric Disorder Topics